Clinical Trial

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2026-03-09
Trial Details
NCT Number NCT07417189
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Solid Tumors, Adult
Enrollment 401 participants
Start Date 2026-03-02
Primary Completion 2028-12-30 (estimated)
Study Completion 2029-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-11